8-K: Crinetics Q3 2025: PALSONIFY Launch Strong, Pipeline Advances

Crinetics Pharmaceuticals reported strong initial uptake for its newly approved drug PALSONIFY, alongside significant pipeline advancements and a reiterated cash runway into 2029, despite increased operating expenses and net loss.

Summary

• PALSONIFY (paltusotine) received U.S. FDA approval on September 25, 2025, for the first-line treatment of adults with acromegaly and has seen an encouraging launch.
• The company's field force has engaged over 95% of top priority healthcare provider targets for PALSONIFY.
• Approximately 95% of filled PALSONIFY prescriptions are from switch patients, and 5% are from naive patients, reflecting the acromegaly population demographics.
• Payer reimbursement has not been a barrier to treatment, with about 50% of filled prescriptions reimbursed.
• Revenues for the third quarter ended September 30, 2025, were $0.1 million, derived from a paltusotine licensing agreement, compared to no revenues in the same period of 2024.
• Research and development expenses increased to $90.5 million in Q3 2025 from $61.9 million in Q3 2024, primarily due to increased personnel costs and clinical/manufacturing activities.
• Selling, general, and administrative expenses rose to $52.3 million in Q3 2025 from $25.9 million in Q3 2024, mainly driven by increased headcount and outside services to support the PALSONIFY commercial launch.
• Net loss for Q3 2025 was $130.1 million, compared to a net loss of $76.8 million for the same period in 2024.
• Cash, cash equivalents, and investments totaled $1.1 billion as of September 30, 2025, down from $1.4 billion as of December 31, 2024.
• The company reiterates its 2025 cash used in operations guidance to be between $340 million and $370 million.
• Crinetics expects its cash, cash equivalents, and investments to be sufficient to fund its current operating plan into 2029.
• Key upcoming milestones include the randomization of first patients in multiple Phase 3 and Phase 2/3 trials for paltusotine and atumelnant in Q4 2025, and the initiation of a Phase 2/3 study for atumelnant in ACTH-dependent Cushing's syndrome in H1 2026.
• The TSHR antagonist program has shifted focus to an alternative candidate with a superior profile, and the SST3 program's IND submission is postponed due to additional preclinical work.

Sentiment

Score: 6

Explanation: The approval and strong initial launch of PALSONIFY are significant positives, establishing Crinetics as a commercial entity with first revenues. The deep pipeline and extended cash runway are also strong points. However, the substantial increase in net loss and operating expenses, coupled with delays in two preclinical programs, temper the overall positive sentiment. The financial results reflect the cost of commercialization and R&D, which is expected but still results in a larger loss.

Positives

• U.S. FDA approval of PALSONIFY for acromegaly on September 25, 2025, marking a historic milestone for the company.
• Encouraging early feedback and strong launch execution for PALSONIFY, with 95% of top priority healthcare provider targets engaged.
• Payer reimbursement has not been a barrier, with approximately 50% of filled PALSONIFY prescriptions reimbursed.
• Robust financial position with cash, cash equivalents, and investments totaling $1.1 billion as of September 30, 2025.
• Reiterated cash runway into 2029, providing long-term financial stability and operational flexibility.
• Advancement of a deep pipeline with five clinical trials progressing, including upcoming Phase 3 initiations for paltusotine in carcinoid syndrome and atumelnant in congenital adrenal hyperplasia (CAH).
• Recorded first revenues of $0.1 million in Q3 2025 from a paltusotine licensing agreement.

Negatives

• Significant increase in net loss to $130.1 million in Q3 2025 from $76.8 million in Q3 2024.
• Substantial increase in research and development expenses to $90.5 million in Q3 2025, up from $61.9 million in Q3 2024.
• Large increase in selling, general, and administrative expenses to $52.3 million in Q3 2025, up from $25.9 million in Q3 2024, primarily due to commercial launch activities.
• Cash, cash equivalents, and investments decreased from $1.4 billion at December 31, 2024, to $1.1 billion at September 30, 2025.
• Shift in focus for the thyroid stimulating hormone receptor (TSHR) antagonist program to an alternative candidate, indicating potential issues with the initial candidate.
• Postponement of the somatostatin receptor 3 (SST3) program's Investigational New Drug (IND) submission due to additional preclinical work needed.

Risks

• Data reported may change following completion or a more comprehensive review of the data related to clinical studies.
• Inability to obtain, maintain, and enforce patents and other intellectual property rights, or prohibitive difficulty/cost to protect such rights.
• Geopolitical events may disrupt Crinetics' business and that of third parties, potentially delaying clinical and preclinical studies, manufacturing, supply chain, or impairing employee productivity.
• Unexpected adverse side effects or inadequate efficacy of product candidates may limit their development, regulatory approval, and/or commercialization.
• Dependence on third parties in connection with product manufacturing, research, and preclinical and clinical testing.
• Uncertainty regarding the success of clinical studies and nonclinical studies.
• Regulatory developments or political changes, including policies related to pricing and pharmaceutical drug reimbursement, in the United States and foreign countries.
• Clinical and preclinical studies may not proceed at the time or in the manner expected, or at all.
• The timing and outcome of research, development, and regulatory review is uncertain, and drug candidates may not advance in development.
• Capital resources may be used sooner than expected, or the cash burn rate may accelerate.
• Future impacts to the business resulting from geopolitical developments outside the company's control.

Future Outlook

Crinetics expects to initiate multiple Phase 3 and Phase 2/3 trials for paltusotine and atumelnant in Q4 2025 and H1 2026, respectively. The first patient for CRN09682 in a Phase 1/2 study is also expected in Q4 2025. Data from atumelnant's Phase 2 study will be shared in early 2026. The company maintains its cash runway into 2029 and reiterates its 2025 cash burn guidance. However, the TSHR antagonist program is shifting focus to an alternative candidate, and the SST3 program's IND submission is postponed.

Management Comments

• "September 25, 2025 was a historic day for Crinetics with the approval of Palsonify for the treatment of people with acromegaly." Scott Struthers, Ph.D., Founder and Chief Executive Officer.
• "For years, acromegaly patients have endured significant challenges with existing therapies." Scott Struthers, Ph.D.
• "Since approval, our team has executed seamlessly to get Palsonify to patients and the launch is off to a very good start." Scott Struthers, Ph.D.
• "Healthcare providers both at pituitary centers and in the community have written prescriptions, and we are seeing uptake in patients switching from prior therapies and in those newly initiating medical therapy." Scott Struthers, Ph.D.
• "With the approval milestone, we are now a fully integrated pharmaceutical company." Scott Struthers, Ph.D.
• "Five clinical trials across our deep pipeline are advancing and our financial position remains robust." Scott Struthers, Ph.D.
• "We are executing with speed and focus on our mission to bring life-changing treatments to the patients who need them most." Scott Struthers, Ph.D.

Industry Context

The approval and initial launch of PALSONIFY position Crinetics as a commercial-stage pharmaceutical company in the endocrine disease space, specifically for acromegaly, a market with existing therapies but also significant unmet needs. The focus on G-protein coupled receptors (GPCRs) and a deep pipeline of novel therapeutics suggests a strategy to address various endocrine conditions, aligning with broader industry trends towards targeted therapies and specialized markets. The increased R&D and SG&A expenses are typical for a company transitioning from a development-stage to a commercial-stage, reflecting investment in both pipeline advancement and market penetration.

Comparison to Industry Standards

• The successful FDA approval and initial commercial launch of PALSONIFY for acromegaly is a significant achievement, comparable to other biotech companies successfully bringing a novel drug to market in a specialty therapeutic area.
• The reported 50% reimbursement rate for filled prescriptions is a positive early indicator for market access, though it will need to be monitored against industry averages for newly launched specialty drugs.
• The rapid engagement with 95% of top priority healthcare providers demonstrates strong commercial execution, which is critical for new drug launches in competitive therapeutic areas.
• The pipeline advancement, including multiple Phase 3 trials, positions Crinetics among peers with robust late-stage development programs, such as those seen in companies like Ipsen (Somatuline Depot) or Novartis (Signifor) which also operate in the acromegaly and neuroendocrine tumor space, though PALSONIFY offers a novel oral option.
• The reiterated cash runway into 2029 is a strong financial position for a biotech company, providing a longer operational horizon compared to many development-stage peers who often face more immediate capital needs.

Stakeholder Impact

• Shareholders: Potential for increased value due to successful drug launch and pipeline progression, but also increased losses and cash burn. Long cash runway provides stability.
• Patients (Acromegaly): Access to a new, oral, once-daily treatment option (PALSONIFY) addressing challenges with existing therapies.
• Healthcare Providers: New treatment option for acromegaly patients, with active engagement from Crinetics' field force.
• Employees: Growth in headcount to support commercial launch and R&D expansion.
• Creditors/Suppliers: Continued operational activity and strong cash position suggest stability.

Next Steps

• Randomize first patients in the CAREFNDR Phase 3 trial of paltusotine in carcinoid syndrome in Q4 2025.
• Randomize first patients in the CALM-CAH Phase 3 study (adults with CAH) and BALANCE-CAH Phase 2/3 study (pediatrics with CAH) for atumelnant in Q4 2025.
• Share glucocorticoid reduction data from Cohort 4 of atumelnant Phase 2 study and 13-week data from Phase 2 open-label extension study in early 2026.
• Initiate Phase 2/3 study for atumelnant in ACTH-dependent Cushing's syndrome (ADCS) in H1 2026.
• First patient to receive CRN09682 in the dose escalation phase of a Phase 1/2 study in Q4 2025.
• Continue preclinical work for the TSHR antagonist program to bring forward an alternative candidate.
• Complete follow-up preclinical work for the SST3 program for IND submission.
• Attend 2025 Stifel Healthcare Conference, Piper Sandler 37th Annual Healthcare Conference, Citi's 2025 Global Healthcare Conference, and 8th Annual Evercore Healthcare Conference in November/December 2025.

Key Dates

Recommendation

The successful FDA approval and initial commercial launch of PALSONIFY are significant positive catalysts, validating Crinetics' R&D efforts and transitioning it into a commercial-stage company. The strong cash position and extended runway into 2029 provide a solid foundation for continued operations and pipeline development. However, the substantial increase in net loss and operating expenses, while expected for a commercial launch and expanded R&D, indicates a period of high cash burn. The delays in two preclinical programs introduce some uncertainty. Given the positive commercial momentum balanced by increased expenses and some pipeline setbacks, a "hold" recommendation is appropriate. Investors should monitor PALSONIFY's sales trajectory, reimbursement trends, and the progress of the late-stage pipeline to assess future growth potential and profitability.

Keywords

Crinetics Pharmaceuticals, CRNX, PALSONIFY, paltusotine, acromegaly, endocrine diseases, neuroendocrine tumors, carcinoid syndrome, atumelnant, congenital adrenal hyperplasia, CAH, ACTH-dependent Cushing's syndrome, ADCS, CRN09682, NDC, SST2-positive tumors, Q3 2025 earnings, FDA approval, biotechnology, pharmaceuticals, clinical trials, drug development, cash runway